Danaher (1DHR) AI Stock Analysis

Danaher

(Milan:1DHR)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Strong cash generationDanaher’s substantial operating and free cash flow provides internal funding for innovation, acquisitions, debt service, and shareholder returns. Strong conversion of earnings into cash also supports resilience through cyclical laboratory and bioprocessing demand, while reducing reliance on external financing.

Negative Factors

Respiratory revenue volatilityRespiratory exposure remains a meaningful source of revenue volatility because demand is influenced by infection rates and flu-season variability. Continued weakness can suppress Diagnostics growth and make consolidated performance less representative of underlying trends in other businesses.

Danaher (1DHR) vs. iShares MSCI Italy ETF (EWI)

Market Cap: EUR 163.25B
Dividend Yield: 0.65%
Average Volume (3M): 35
Price to Earnings (P/E): 37.9
Beta (1Y): 0.42
Revenue Growth: 0.21%
EPS Growth: 18.69%
Country: Italy
Employees: 59,000
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Diagnostics & Research

Danaher Business Overview & Revenue Model

Company Description

Danaher Corporation is a diversified global technology and science company that specializes in developing, manufacturing, and distributing a wide array of professional, medical, industrial, and commercial products and services across the world. The o...

Danaher Earnings Call Summary

Earnings Call Date:Oct 20, 2026(Q3-2026)|% Change Since:3.90%|Next Earnings Date:Jan 26, 2027

Earnings Call SentimentPositive

The call was broadly positive. Danaher delivered better-than-expected revenue, earnings, margins, and cash flow; raised full-year EPS guidance; reported improving trends across biotechnology, life sciences, and diagnostics; and highlighted strong orders, AI initiatives, and acquisition integration. The main challenges were respiratory-related revenue declines, North American weakness, academic and selected discovery-market softness, and a measured 4%-5% initial 2027 growth framework. Highlights significantly outweighed the lowlights.

Positive Updates

Third-Quarter Results Exceeded Expectations

Danaher reported third-quarter sales of $6.6 billion, core revenue growth excluding respiratory revenue of 5.5%, and a nearly 30% adjusted operating profit margin. Results were ahead of expectations, reflecting improved end-market conditions and strong commercial and operational execution.

Negative Updates

Growth Has Not Consistently Reflected Portfolio Potential

The CEO acknowledged that growth over the past several years has not consistently reflected the full potential of Danaher's portfolio and said the company has an opportunity to accelerate sustainable core revenue growth and gain share more consistently.

Company Guidance

For the fourth quarter, Danaher expects core revenue growth excluding respiratory revenue to be in the 4%-5% range, respiratory revenue to be an approximately 150 basis point headwind, and adjusted operating profit margin to be approximately 29.5%. For full year 2026, adjusted diluted net EPS guidance is $8.57-$8.62 versus the prior range of $8.45-$8.60, representing double digit year-over-year EPS growth; bioprocessing remains expected to deliver mid-single digit core revenue growth. For 2027, 4%-5% core revenue growth excluding respiratory revenue is the right starting point as we sit today, with more quantitative and detailed guidance to be provided in January. Respiratory revenue is planned at $1.5 billion this year and is also the right starting point for next year, with a couple hundred million dollars of bookends around that number. Cytiva is expected to deliver sustainable high single digit long-term revenue growth, while reshoring could be a billion-dollar market opportunity in the U.S., mostly starting in 2028.

Danaher Risk Analysis

Danaher disclosed 43 risk factors in its most recent earnings report. Danaher reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

1 New Risk

1.Military conflicts can adversely affect our business and financial statements.Q2, 2026

Danaher Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

IT:1DHR against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IDXX	80Outperform	$43.42B	38.71	71.96%	―	12.77%	18.22%
TMO	77Outperform	$257.71B	36.70	13.31%	0.26%	8.27%	9.59%
A	75Outperform	$49.30B	34.35	20.47%	0.58%	8.60%	19.07%
MTD	75Outperform	$33.56B	37.60	-1199.91%	―	6.91%	12.43%
WAT	57Neutral	$45.46B	115.10	1.88%	―	52.47%	-63.86%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

IT:1DHR and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IT:1DHR	Danaher Corporation	207.90	24.12	13.12%
A	Agilent Technologies	174.87	31.26	21.77%
IDXX	Idexx Laboratories	551.21	-171.73	-23.75%
MTD	Mettler-toledo International	1674.81	267.93	19.04%
TMO	Thermo Fisher Scientific	697.00	134.10	23.82%
WAT	Waters Corp	462.72	117.13	33.89%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Danaher AI Stock Analysis